Literature DB >> 7471936

[Surgical treatment of instable per- and subtrochanteric femure fractures with the 130 degrees double-T-plate. Clinico-experimental report].

E Teubner, H Fischer.   

Abstract

1. Operative treatment of instable inter- and subtrochanteric fractures with a new 130 degrees double-T plate allowed, in spite of high-risk patients (age mean = 85 years, multimorbidity approximately 92%), full maximum stress by the third day after the operation and a shorter time of hospitalisation of 22.5 days. Lethality was 12.2%. - 2. Load experiments showed that the double-T-profiled 130 degrees plate with increased lateral moment of resistance could support a weight five times greater than that supported by 130 degrees implants with transversal blades, and had a resistance to bending two-and-a-half times greater than hip compression screws. In an 'intertrochanteric' position the plate could carry 3000 N and in a 'subtrochanteric' position 1000 N without permanent deformity. - 3. A review was carried out in 62.6% of the patients 6-32 months after double-T-plate osteosynthesis. Acceptable results were revealed in 80.7%. Of the 98 patients reviewed 44% had complete freedom of movement, 34.6% walked with a stick, 15.4% required crutches and 6% were unable to walk.

Entities:  

Mesh:

Year:  1980        PMID: 7471936

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  3 in total

1.  Wave plate osteosynthesis as a salvage procedure.

Authors:  G Blatter; B G Weber
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

2.  [Incidence of complications and early mortality in surgical management of coxal femoral fractures].

Authors:  J Raunest; A Kaschner; E Derra
Journal:  Langenbecks Arch Chir       Date:  1990

3.  Treatment of subtrochanteric fractures of the femur: reduction on the traction table and fixation with dynamic condylar screw.

Authors:  G Blatter; M Janssen
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.